



#### Lower May Not Be Better Systolic Blood Pressure And Risk Of Major Adverse Limb Events In Patients With Symptomatic Peripheral Artery Disease After Revascularization: Insights From VOYAGER PAD

Cullen E. Buchanan, MD, Michael Szarek, Eike Sebastian Debus, MD, PhD, Manesh R. Patel, MD, Mark R. Nehler, MD, Sonia S. Anand, MD, Connie N. Hess, MD, MHS, Judith Hsia, MD, Eva Muehlhofer, MD, Lloyd P. Haskell, MD, MBA, Scott D. Berkowitz, MD, Rupert M. Bauersachs, MD, Marc P. Bonaca, MD, MPH

#### Cullen Buchanan, MD





#### **Disclosures**


#### Cullen Buchanan, MD<sup>1,2</sup>: No conflicts/disclosures

## <sup>1</sup>University of Colorado Anschutz School of Medicine <sup>2</sup>Medical College of Wisconsin





### Goals



1. Emphasize a multimodal approach to the treatment of symptomatic peripheral artery disease (PAD), including blood pressure (BP) and lower extremity revascularization (LER)

2. Highlight the current uniform approach to blood pressure management

3. Consider an individualized approach to BP management in patients with symptomatic PAD in the first month following LER





# Background

- PAD affects >200 million individuals worldwide
- Hypertension (HTN) is a significant risk factor for major adverse cardiovascular events (MACE) and there are well established optimal BP targets for MACE prevention
- Less intensive BP control is allowed to minimize end organ damage in certain settings such as acute ischemic stroke and acute kidney injury

#### 2017 ACC/AHA Hypertension Guidelines

#### 9.5. Peripheral Artery Disease

Recommendation for Treatment of Hypertension in Patients With PAD References that support the recommendation are summarized in Online Data Supplement 45.				
COR	LOE	Recommendation		
I	B-NR	1. Adults with hypertension and PAD should be treated similarly to patients with hypertension without PAD. <sup>S9.5-1-S9.5-4</sup>		



# Background

- Re-analysis of the ALLHAT trial investigated the effect of different antihypertensive medications on cardiovascular events, including PAD related events.
- Systolic blood pressure (SBP) <120mmHg was associated with a 26% higher rate of major adverse limb events (MALE) in stable patients with PAD

#### PAD event hazard ratios of individual blood pressure categories.

Sub-HR	95% CI	P-value	mm Hg		
1.26	1.05-1.52	0.015	< 120	SBP	
	Reference		120 – 129		
0.94	0.80-1.10	0.41	130 – 139		
1.08	0.91-1.27	0.40	140 - 149		▶ <b></b> •i
1.12	0.92-1.37	0.27	150 - 159		
1.21	1.00-1.48	0.050	≥ 160		
1.72	1.38 - 2.16	<0.001	< 60	DBP	
1.18	1.02 - 1.37	0.02	60 - 69		
	Reference		70 – 79		•
0.85	0.75 - 0.97	0.02	80 - 89		
0.91	0.74 - 1.11	0.35	90 – 99		
0.71	0.46 - 1.08	0.11	≥ 100		J
1.21	1.01 - 1.45	0.04	< 45	PP	, (
	Reference		45 - 54		•
1.02	0.87 - 1.19	0.81	55 - 64		
1.29	1.10 - 1.52	0.002	65 – 74		
1.49	1.26 - 1.76	<0.001	≥ 75		·
				0 0	0.5 1 1.5 2 2
					Hazard Ratio


Figure 2. PAD event hazard ratios of individual blood pressure categories. Association of categories of systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure (PP) with lower extremity PAD events.

Nathan K. Itoga. Circulation. Association of Blood Pressure Measurements With Peripheral Artery Disease Events, Volume: 138, Issue: 17, Pages: 1805-1814, DOI: (10.1161/CIRCULATIONAHA.118.033348)




### **VOYAGER PAD TRIAL DESIGN**

6564 Patients with Symptomatic Lower Extremity PAD Undergoing Peripheral Revascularization





## **Risk of MACE and MALE by SBP 1 Month After LER**



Risk of MACE based on SBP 1 month following LER


\*Splines estimated in proportional hazard models with adjustment for treatment assignments. Not adjusted for other possible confounders. Risk of MALE based on SBP 1 month following LER

# \*Every 5mmHg decrease in SBP <120mmHg is associated with 7% increase of MALE





### Risk of MALE by SBP 1 Month After LER Stratified by Index Revascularization Type



**Risk** of MALE based on SBP 1 month following Surgical LER

Risk of MALE based on SBP 1 month following Endovascular LER

8

Voyager pad 🌌



\*Splines estimated in proportional hazard models with adjustment for treatment assignments. Not adjusted for other possible confounders.

## **Summary & Conclusions**

- Patients with PAD are at an increased risk of MALE
- An inverse relationship between systolic blood pressure at 1 month following LER and risk for MALE was observed, consistent with analyses from ALLHAT
- The pattern appeared consistent regardless of index revascularization type
- Further investigation is needed to determine whether the higher rates of MALE that were associated with lower systolic blood pressures was independent of other risk factors and whether there is a true causal relationship between BP and MALE in PAD





## **THANK YOU!**



